Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic.

IF 1.2 4区医学 Q4 HEALTH POLICY & SERVICES

Journal of Health Care for the Poor and Underserved Pub Date : 2026-01-01 DOI:10.1353/hpu.2026.a982969

Crystal Deas, Laurel Uhomba, Kayla Snow

{"title":"Real-World Impact of Weekly Dulaglutide and Semaglutide on Hba1c and Weight in a Predominantly Underrepresented Demographic.","authors":"Crystal Deas, Laurel Uhomba, Kayla Snow","doi":"10.1353/hpu.2026.a982969","DOIUrl":null,"url":null,"abstract":"Background: African Americans are underrepresented in real-world studies of GLP-1 receptor agonists (RA) for type 2 diabetes.Objectives: This study evaluates the effects of weekly dulaglutide and semaglutide on glycated hemoglobin (HbA1c) and weight in a predominantly African American population.Methods: A retrospective chart review was conducted at an adult medicine clinic. Patients 19 years of age or older with at least 26 weeks of dulaglutide or semaglutide treatment and recorded baseline and follow-up HbA1c and weight were included.Results: Among 91 patients-85.7% African American, 67.0% female, mean age 56.4 years-the mean GLP-1 RA treatment duration was 14.9 months. Glycated hemoglobin decreased by 2.39% (p<.001), and weight dropped by 4.76 kg (p<.001). High-dose dulaglutide significantly lowered HbA1c compared with low-dose (p=.023).Conclusion: Weekly dulaglutide and semaglutide significantly reduced HbA1c and weight. Further research is needed to explore factors influencing differential responses.","PeriodicalId":48101,"journal":{"name":"Journal of Health Care for the Poor and Underserved","volume":"37 1","pages":"270-286"},"PeriodicalIF":1.2000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Care for the Poor and Underserved","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1353/hpu.2026.a982969","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: African Americans are underrepresented in real-world studies of GLP-1 receptor agonists (RA) for type 2 diabetes.

Objectives: This study evaluates the effects of weekly dulaglutide and semaglutide on glycated hemoglobin (HbA1c) and weight in a predominantly African American population.

Methods: A retrospective chart review was conducted at an adult medicine clinic. Patients 19 years of age or older with at least 26 weeks of dulaglutide or semaglutide treatment and recorded baseline and follow-up HbA1c and weight were included.

Results: Among 91 patients-85.7% African American, 67.0% female, mean age 56.4 years-the mean GLP-1 RA treatment duration was 14.9 months. Glycated hemoglobin decreased by 2.39% (p<.001), and weight dropped by 4.76 kg (p<.001). High-dose dulaglutide significantly lowered HbA1c compared with low-dose (p=.023).

Conclusion: Weekly dulaglutide and semaglutide significantly reduced HbA1c and weight. Further research is needed to explore factors influencing differential responses.

查看原文本刊更多论文

在代表性不足的人群中，每周服用杜拉鲁肽和西马鲁肽对Hba1c和体重的实际影响。

背景：非裔美国人在GLP-1受体激动剂（RA）治疗2型糖尿病的实际研究中代表性不足。目的：本研究评估了以非裔美国人为主的人群中，每周服用杜拉鲁肽和西马鲁肽对糖化血红蛋白（HbA1c）和体重的影响。方法：对某成人医学门诊进行回顾性图表分析。患者年龄≥19岁，接受至少26周的dulaglutide或semaglutide治疗，并记录基线和随访HbA1c和体重。结果：91例患者中，85.7%为非裔美国人，67.0%为女性，平均年龄56.4岁，GLP-1 RA的平均治疗时间为14.9个月。糖化血红蛋白下降2.39% (p < 0.01)，体重下降4.76 kg （p < 0.01）。与低剂量相比，高剂量杜拉鲁肽显著降低HbA1c （p= 0.023）。结论：每周服用dulaglutide和semaglutide可显著降低HbA1c和体重。影响差异反应的因素有待进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Health Care for the Poor and Underserved Multiple-

CiteScore

2.00

自引率

7.10%

发文量

154

期刊介绍： The journal has as its goal the dissemination of information on the health of, and health care for, low income and other medically underserved communities to health care practitioners, policy makers, and community leaders who are in a position to effect meaningful change. Issues dealt with include access to, quality of, and cost of health care.